Pleiotropic pathway modifier compounds and method of treating diseases

A compound represented by Formula I,

• wherein
• X is CH2 or C═O,
• R1 in each instance is independently selected from the group consisting of 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, C1-4alkyl, OC1-4alkyl, NRaRb, halo C1-4alkyl, halogen, OH, CN, phenyl and 5- or 6-membered heteroaryl, wherein the phenyl and 5- or 6-membered heteroaryl are optionally substituted with one or more substituents selected from the group consisting of C1-4alkyl, OC1-4alkyl, NRaRb, halo C1-4alkyl, halogen, OH, and CN;
• R2 is OH;
• Ra and Rb in each instance is independently H or C1-4alkyl;
• A is C1-3alkylene or void,
• M is O, OC1-3alkylene, NRa, NHC(O)NH, O(CO)NH, NHC(O)O, or NHC(O), wherein O of OC1-3alkylene is bonded to A or the B ring when A is void;
• L1 is NH, 3-6 membered heterocyclic, 6-membered aryl or 6-membered heteroaryl, haloC1-2alkylene, C1-3alkylene or void, wherein the aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of C1-4alkyl, ORa, SH, NRaRb, 3-6 membered cycloalkyl, COORa, CN, halogen, 3-6 membered cycloalkyl, OC1-4alkyl, and haloC1-4alkyl,
• L2 in each instance is independently selected from the group consisting of 3-6 membered heterocylic, 6-membered aryl, 6-membered heteroaryl, —(CH2)aC(O)NRa—, —C(O)NRa—, —(CH2)aC(O)NRa(CH2)b—, —(CH2)a—, —(CH2)aO(CH2CH2O)c—, —(CH2)aS, —(CH2)aheterocyclyl-, —(CH2)aC(O)—, —(CH2)a NRa—, —CRa═N—NRa—, —CRa═N—O—, —CRa═N—NRb—CO—, —N═N—CO—, —S—S—, and any combination thereof, wherein a, b, and c are each an integer selected from 0 to 25, all subunits included;
• L3 is C1-20alkylene, halo-C1-20alkylene, C2-20alkenlene, C2-20alkynlene or void;
• m is 0, 1, 2 or 3;
• n is an integer selected from 0 to 25, all subunits included;
• or a pharmaceutically acceptable salt thereof,
• provided that when A, L1 and (L2)n are void and M is NHC(O)NH, or NHC(O), M is not in an ortho position to X.